SCHEDULE 13G/A: BlackRock Discloses 7.6% Passive Stake in AstraZeneca PLC
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in AstraZeneca PLC as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 117,761,076 shares of AstraZeneca PLC common stock.
- This ownership represents 7.6% of the total outstanding common stock of AstraZeneca PLC.
- BlackRock holds sole voting power over 106,948,172 shares and sole dispositive power over 117,761,076 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of AstraZeneca PLC.
- This filing is Amendment No. 3 to the Schedule 13G, indicating previous filings have been made.
- Various BlackRock subsidiaries and affiliates contribute to the aggregate beneficial ownership, with none individually holding more than 5% of the class, except for entities listed in Exhibit 99 that beneficially own 5% or greater.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing beneficial ownership. It does not contain operational or financial performance data for AstraZeneca PLC, nor does it indicate any strategic shifts or significant events that would alter sentiment. It is a neutral, factual disclosure of an institutional holding.
Positives
- BlackRock, a major institutional investor, holds a significant 7.6% stake in AstraZeneca PLC, indicating substantial institutional confidence in the company.
- The holding is for investment purposes in the ordinary course of business, not for control, suggesting stability in the ownership structure and no immediate intent for activist intervention.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding AstraZeneca PLC's future performance or BlackRock's investment strategy beyond the stated purpose of holding shares in the ordinary course of business.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing reflects a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, regarding its significant passive investment in AstraZeneca PLC, a leading global pharmaceutical and biotechnology company. Such large institutional holdings are common for major public companies and indicate a broad market presence by institutional investors.
Comparison to Industry Standards
- This Schedule 13G filing is a standard regulatory disclosure for institutional investors holding more than 5% of a company's shares, aligning with common industry practices for transparency.
- BlackRock's 7.6% stake in AstraZeneca PLC is a substantial passive investment, consistent with the portfolio diversification strategies of large asset management firms.
- The document does not provide specific comparable companies, projects, or results to assess AstraZeneca's performance against industry standards; rather, it focuses on BlackRock's ownership position.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, revoking the previous one dated April 30, 2023. This document authorizes specific individuals to execute and file various ownership or control-person reporting requirements on behalf of BlackRock and its direct and indirect subsidiaries and affiliates. | January 21, 2025 | Streamlines regulatory compliance for BlackRock by designating authorized signatories for SEC and other governmental filings, ensuring efficient and timely disclosure processes. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake in AstraZeneca PLC, confirming a large, passive investment by BlackRock, Inc.
- Regulatory Authorities: Fulfills the mandatory disclosure requirements under SEC Rule 13G, ensuring compliance and market transparency.
Next Steps
- BlackRock, Inc. will continue to hold its shares in AstraZeneca PLC in the ordinary course of business.
- BlackRock, Inc. will continue to comply with SEC reporting requirements for its beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney for BlackRock, Inc. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 04/23/2025 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, AstraZeneca, Schedule 13G, beneficial ownership, institutional investor, common stock, pharmaceuticals, biotechnology, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.